Navigation Links
AlphaRx Receives China Patent on Its Drug Delivery Platform
Date:8/10/2009

MARKHAM, ON, Aug. 10 /PRNewswire-FirstCall/ - AlphaRx Inc. (OTC BB:ALRX.OB - News), an emerging biopharmaceutical company utilizing proprietary drug delivery technology to develop novel formulations of drugs, is pleased to announce that it has been granted a comprehensive patent in China for its topical platform technology entitled "Vehicle For Topical Delivery of Anti-Inflammatory Compounds." The platform is an integral part of the Company's clinical stage product candidate Indaflex(TM).

"China represents a major opportunity for AlphaRx because of its huge and growing market for innovative therapeutics products," said AlphaRx President and CEO Michael Lee. "The granting of this patent from the Chinese government intellectual property authority helps protect our innovative drug delivery technology and further endorses our competitive position in China."

In April 2006, AlphaRx licensed the global rights (with the exception of Asia and Mexico) for Indaflex(TM) to Proprius Pharmaceuticals, Inc. Under the terms of the agreement, AlphaRx is eligible to receive milestone payments of up to $116 million for the successful development and commercialization of Indaflex(TM), as well as double-digit royalties on sales. Proprius was acquired by Cypress Biosceince Inc., in March 2008.

About Indaflex(TM)

Indaflex(TM) is AlphaRx's topical NSAID (Non-Steroidal Anti-inflammatory Drug) formulation under clinical development for the symptomatic treatment of osteoarthritis. Arthritis is the most common chronic disease in North America and afflicts an estimated 10% of the world's population. Indaflex's active ingredient, Indomethacin, has a long-standing and proven clinical treatment record. With AlphaRx's enhanced proprietary delivery system, the company believes its' clinical effectiveness will be significantly enhanced compared to other topical preparations. Topical Indaflex(TM) delivery, the company hopes, may circumvent the significant GI side-effects commonly found with orally ingested NSAID's.

About AlphaRx Inc.

AlphaRx is a specialty pharmaceutical company dedicated to developing proven therapies by reformulating FDA approved and marketed drugs which through the application of its proprietary site-specific nano drug delivery technology, offers improved medical benefits and a potential for significant commercial product development.

Forward Looking Statements:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.

This press release is available on the company's official on-line investor relations site for investor commentary, feedback and questions.


'/>"/>
SOURCE AlphaRx Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. AlphaRx and Venturepharm Announce Collaboration Agreement
2. AlphaRx Presents Positive Preclinical Data on Zysolin(TM) Inhalable Nanoparticles at Controlled Release Society Annual Meeting
3. AlphaRx Unveils its China Strategy
4. AlphaRx Reports Positive Preclinical Data on GAI-122 Against Liver Disease
5. AlphaRx and Gaia BioPharma Report Positive Efficacy Results in a Pre-Clinical Trial of GAI-122 Injectable Nano-emulsion for Post-operative Delirium
6. AlphaRx Shareholder Update
7. AlphaRx and Gaia BioPharma Provide GAI-122 Development Update
8. AlphaRx Signs Cooperative Research and Development Agreement with US Army
9. AlphaRx Provides Corporate and Development Update
10. AlphaRxs Indaflex(TM) Continues its Clinical Development
11. AlphaRx CEO Accumulates More Company Shares
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... ... January 20, 2017 , ... Vitamin Well ... VW+ 002. The drinks have been produced in collaboration with Zlatan Ibrahimovic and ... your workout. , After a successful launch in Sweden last year, the next ...
(Date:1/20/2017)... ... January 20, 2017 , ... “The Angel”: a heartwarming and earnest tale ... each of his children. “The Angel” is the creation of published author, Marjorie Lund-Fontaine, ... City, and impassioned writer. , When asked of her new book, Marjorie says, “‘The ...
(Date:1/20/2017)... ... ... Forgive You”: a fine examination of how God handles sin, including how to let ... Stephen Miller, who, for over ten long years has been waiting to release this powerful ... Tobago, he has been serving the Lord for over twenty years, and he has been ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Christmas in Suffolk”: a story of ... Seymour, who lives in Lafayette, Indiana where she works in a daycare and looks ... writes. , Published by Christian Faith Publishing, Sara Seymour’s new book is an adventure ...
(Date:1/20/2017)... ... January 20, 2017 , ... “Knowledge is God’s Lighthouse”: a moving ... is God’s Lighthouse” is the creation of published author, Gene Gaapf, a retired truck ... , “I have been writing since high school and have many different titles,” ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... January 19, 2017 The global  pacemaker market  is expected ... Grand View Research, Inc. The heightening prevalence of cardiac conditions coupled with the ... Pacemaker globally. In addition, technological enhancements in these devices are supporting the expansion ... ... Grand View Research Logo ...
(Date:1/19/2017)...   Synthetic Biologics, Inc. (NYSE MKT: ... to preserve the microbiome to protect and restore ... initiate a Phase 2b/3 adaptive pivotal trial for ... designed to reduce methane production by certain microorganisms ... treat the underlying cause of irritable bowel syndrome ...
(Date:1/18/2017)... DALLAS , Jan. 18, 2017  Aprima ... health records (EHR), practice management (PM) and revenue ... announced the acquisition of a former reseller Healthcare ... part of the agreement, Aprima will assume full ... providers in 125 medical practices across 15 states. ...
Breaking Medicine Technology: